Focus on a new cycle of medicine!2022 China Health Industry Summit's Medical Innovation Summit on the 29th online see

The 21st Century Economic Herald reporter Ji Yuanyuan reported that in recent years, with the continuous advancement of China's pharmaceutical and political reform, the development of China's innovative medicine has entered the golden age, and the Chinese pharmaceutical health industry has ushered in a new historical chapter of the Great River.

Under the state of vigorously promoting the development of biomedical innovation, my country has gradually changed from the initial pharmaceutical innovation and runners to merging, and even leaders. A group of local companies dedicated to independent innovation have emerged, and they strode towards the international stage. For example, the anti -tumor drugs, the anti -tumor drugs, Soffinib, Savetinib, etc., are moving from the laboratory to the market to benefit the majority of patients.

The "White Paper Development of China Innovation Pharmaceutical Companies in 2022" pointed out that in the past two decades, the Chinese pharmaceutical market has rely on the advancement of medical reform and the expansion of medical insurance. From the perspective of market sales, innovative drugs account for only 25%of the drug sales market in China. However, with the development of policies such as the consistency evaluation and volume procurement of generic drugs, the development space of generic drugs is getting narrower and narrower, and the development of innovative drugs has become the focus of Chinese pharmaceutical companies.

Under the resonance of policies, industries, talents, and capital, the innovation of Chinese biomedical innovation ushered in "acceleration", and the pace of listing of new drugs also entered the fast lane. However, since the second half of 2021, the capital market has changed, and the biomedical sector has begun to fluctuate down. Entering 2022, under the impact of multiple uncertain factors, the cooling of biomedical investment and financing markets was obvious, and enterprises with severe homogeneity of product pipelines faced tests.

This also makes the entire industry put forward higher requirements for enterprise source innovation and differentiated competition capabilities. However, in the context of the increasingly severe trend of aging, China still has a large number of clinical needs that have not been met. In the long run, biomedical companies are still a major rising industry. In this context, the real innovative research and development of products and enterprises will definitely be recognized by the market and capital.

According to the data reported by IQVIA's global R & D trends, the global biopharmaceutical research and development results in 2021 reached a record high again, with a total of 84 new activated substances listed. From the perspective of R & D pipelines, tumors, neurological diseases, and rare diseases are currently key areas of global R & D and innovation. Technically speaking, "precision medical care" is an inevitable trend in the future, especially targeted biopharmaceuticals and the next generation of therapies have occupied half of the rivers and mountains in tumor research and development.

In the global innovation landscape, only China's research and development proportion rose rapidly between 2016 and 2021. Especially in the field of the next generation of therapy, according to data compiled by IQVIA, China's cells and gene therapy pipelines have ranked second in the world. It is far more developed than France, the United Kingdom, and Germany. The opportunity to use new drugs with developed countries with developed countries has continued to increase, and the cost of medication for Chinese patients has also begun to decline.

At present, in the major types of cancer diseases in my country, most patients with lung cancer, breast cancer, liver cancer, and bowel cancer are in the middle and late stages. The best time to treat the best treatment brings great harm to the health of the people. Faced with high incidence, helping to achieve precise testing of tumor patients has become a common topic of the whole society. Especially with the acceleration of the aging trend of China's population, the continuous increase in the proportion of new cancer is urgent to promote early treatment of early screening of cancer.

To this end, in July 2019, the State Council issued the "Opinions on the Implementation of Action of Healthy China", emphasizing advocating active prevention of cancer, promoting early screening, early diagnosis, early treatment, reducing the incidence and mortality of cancer, and an orderly expansion of cancer screening Scope of investigation. By 2022 and 2030, the 5 -year survival rate of overall cancer will not be less than 43.3%and 46.6%, respectively.

Cancer screening and early diagnosis and early treatment are one of the effective ways to prevent and control cancer. Cancer screening is in the crowd, using fast, simple inspection, inspection or other methods to perform physical examinations for common cancer. Through examination, the subject knows that he has the risk of cancer. Early detection, early diagnosis and early treatment. There is no doubt that, with the promotion of such a large market demand and policy, China's cancer screening and testing industry will be a blue ocean. For industry companies, the market, policies, and timing are now available. It is time to show their core technology. It's time!

Based on this, on September 29, 2022, under the guidance of Southern Finance and Economics Group, domestic digital think tank financial media leaders "21st Century Economic Herald", hosted by the 21st Century New Health Research Institute, and co -sponsored by Guangfa Securities "2022 China University The Health Industry Summit's Medical Innovation Summit and "Outstanding Case of Health China • 21cc" will be officially released online. The conference will invite industry experts, industry leaders, technical pioneers, and investment institutions to start dialogue and exchanges on hot topics such as Chinese pharmaceutical innovation, early diagnosis and early treatment of cancer, early diagnosis and early treatment, and drugs. future.

In addition, the 21st Century New Health Research Institute will also release the "2022 China Cancer Early Sieve Development Trends Report" and "2022 Internet Medical+Cancer Report" at the conference.

- END -